Faber lawyers and contract specialists have been working with 3 of the dynamic companies on this year’s list – and 1/3 of the companies listed in the past five years or their scientific founders.
On September 26, 2017, FierceBiotech released their eagerly-anticipated annual “Fierce 15” list – “The FierceBiotech Fierce 15 is a hunt for the biggest ideas in biotech, the most daring characters in biopharma, and entrepreneurs doing things that haven't been done before. Fifteen privately held drug developers or platform biotechs with the potential to have a huge impact on the treatment of human diseases. The Fierce 15 celebrates the spirit of being "fierce"--championing innovation and creativity, even in the face of intense competition--and has recognized a number of distinguished biotechs over the years.”
The firm has acted as transactional counsel to 3 of these dynamic companies: Gritstone Oncology, Magenta Therapeutics and Rubius Therapeutics. During the year, Sumy Daeufer and Tim LaBua helped Alnylam Pharmaceuticals (a “Fierce 15” alumnus) enter into an important strategic alliance with Vir Biotechnology, another 2017 “Fierce 15” honoree (see press release here). And, for the 75 companies listed as “Fierce 15” honorees in the past five years, the firm has acted as transactional counsel, or as counsel to the primary scientific founders or lead investors, to 25 of these companies.